Ferronova is an Australian biotechnology company commercialising hybrid magnetic and fluorescent nanoparticles for MRI and image guided surgery and therapies.
Ferronova's first-generation product is a combination device/drug system designed to map the lymphatics in gastro-intestinal cancers to aid in more precise surgery and MRI guided therapy, and to improve the staging of the cancer by detecting micro-metastasis in lymph nodes where they would otherwise be missed.
Upper gastro-intestinal cancers have the poorest outcomes among all cancers, with even localised cancers having only 42-60% 3-year survival.
A 15 patient first-in-human human trial has been completed, a 40-patient colorectal human trial is in progress, and an upper gastro-intestinal trial is to commence in 2023.
See Ferronova's website for more details.